Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway

Jiang,Kehua; Chen,Hongbo; Tang,Kun; Guan,Wei; Zhou,Hui; Guo,Xiaolin; Chen,Zhiqiang; Ye,Zhangqun; Xu,Hua

doi:10.3892/ol.2017.7298

Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway

Authors:
- Kehua Jiang
- Hongbo Chen
- Kun Tang
- Wei Guan
- Hui Zhou
- Xiaolin Guo
- Zhiqiang Chen
- Zhangqun Ye
- Hua Xu
View Affiliations

Affiliations: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Urology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China
Published online on: October 31, 2017 https://doi.org/10.3892/ol.2017.7298
Pages: 167-174
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Puerarin, as a novel oncotherapeutic agent, may exert anticancer effects and inhibit the proliferation of cancer cells. To explore the effects of puerarin on human bladder cancer cells, and to elucidate the potential mechanism underlying these effects, a Cell Counting Kit‑8 assay was used to examine the proliferation of T24 and EJ cells following puerarin treatment. The effects of puerarin treatment on the cell cycle were detected by flow cytometry (FCM), while puerarin-induced cell apoptosis was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling and FCM, and the cellular ultrastructural morphological changes were observed by transmission electron microscopy. Cell invasion was examined using a Transwell assay with Matrigel. The expression levels of mechanistic target of rapamycin (mTOR), phosphorylated (p)‑mTOR, p70‑S6 kinase (p70S6K) and p‑p70S6K proteins in the mTOR signaling pathway were then assessed by western blotting. The results demonstrated that puerarin may inhibit bladder cancer cell viability, block the cell cycle in the G0/G1 phase and induce apoptosis in bladder cancer cells. The expression levels of p‑mTOR and p‑p70S6K proteins were downregulated, while no change was observed in the expression levels of mTOR and p70S6K proteins when T‑24 and EJ cells were treated by puerarin. In the present study, puerarin was demonstrated to inhibit the viability of human bladder cancer cells. These effects may be due to the puerarin‑induced downregulation of proteins in the mTOR/p70S6K signaling pathway, and the present study may provide the experimental basis for puerarin to be considered as a promising novel anti‑tumor drug for the treatment of bladder cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Redorta J Palou, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
3	Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar : PubMed/NCBI
4	Schenk-Braat EA and Bangma CH: Immunotherapy for superficial bladder cancer. Cancer Immunol Immunother. 54:414–423. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shen Z, Shen T, Wientjes MG, O'Donnell MA and Au JL: Intravesical treatments of bladder cancer: Review. Pharm Res. 25:1500–1510. 2008. View Article : Google Scholar : PubMed/NCBI
6	Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, Beckers GMA and Moorselaar RJAV: Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: A prospective multicentre randomised study in 2243 patients. Eur Urol. July 10–2017.(Epub ahead of print). View Article : Google Scholar
7	Deng T, Liu B, Duan X, Zhang T, Cai C and Zeng G: Systematic review and cumulative analysis of the combination of mitomycin C plus Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer. Sci Rep. 7:31722017. View Article : Google Scholar : PubMed/NCBI
8	Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM and Gleave ME: Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int. 101:1347–1355. 2008. View Article : Google Scholar : PubMed/NCBI
9	Jiang SJ, Ye LY and Meng FH: Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review. Oncol Lett. 11:2751–2756. 2016.PubMed/NCBI
10	Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E and Désaubry LG: Cancer wars: Natural products strike back. Front Chem. 2:202014. View Article : Google Scholar : PubMed/NCBI
11	Orang-Ojong BB, Munyangaju JE, Wei MS, Lin M, Wei FG, Foukunang C and Zhu Y: Impact of natural resources and research on cancer treatment and prevention: A perspective from Cameroon. Mol Clin Oncol. 1:610–620. 2013. View Article : Google Scholar : PubMed/NCBI
12	Keung WM and Vallee BL: Kudzu root: An ancient Chinese source of modern antidipsotropic agents. Phytochemistry. 47:499–506. 1998. View Article : Google Scholar : PubMed/NCBI
13	Kim MH, Kim SH and Yang WM: Mechanisms of action of phytochemicals from medicinal herbs in the treatment of Alzheimer's disease. Planta Med. 80:1249–1258. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhang X, Xiong J, Liu S, Wang L, Huang J, Liu L, Yang J, Zhang G, Guo K, Zhang Z, et al: Puerarin protects dopaminergic neurons in Parkinson's disease models. Neuroscience. 280:88–98. 2014. View Article : Google Scholar : PubMed/NCBI
15	Tan Y, Liu M and Wu B: Puerarin for acute ischaemic stroke. Cochrane Database Syst Rev. 23:CD0049552008.
16	Wang Q, Wu T, Chen XY, Duan X, Zheng J, Qiao J, Zhou L, Wei J and Ni J: WITHDRAWN: Puerarin injection for unstable angina pectoris. Cochrane Database Syst Rev: CD004196. 2016. View Article : Google Scholar
17	Liu LJ, Liu LQ, Bo T, Li SJ, Zhu Z, Cui RR and Mao DA: Puerarin suppress apoptosis of human osteoblasts via ERK signaling pathway. Int J Endocrinol. 2013:7865742013. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Yang ZR, Guo XF, Song J, Zhang JX, Wang J and Dong WG: Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer. Mol Med Rep. 10:2535–2541. 2014. View Article : Google Scholar : PubMed/NCBI
19	Yang JA, Li JQ, Shao LM, Yang Q, Liu BH, Wu TF, Wu P, Yi W and Chen QX: Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines. Int J Clin Exp Med. 8:10132–10142. 2015.PubMed/NCBI
20	Guo XF, Yang ZR, Wang J, Lei XF, Lv XG and Dong WG: Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma. Mol Med Rep. 11:2562–2568. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yu Z and Li W: Induction of apoptosis by puerarin in colon cancer HT-29 cells. Cancer Lett. 238:53–60. 2006. View Article : Google Scholar : PubMed/NCBI
22	O'Toole CM, Povey S, Hepburn P and Franks LM: Identity of some human bladder cancer cell lines. Nature. 301:429–430. 1983. View Article : Google Scholar : PubMed/NCBI
23	Ching CB and Hansel DE: Expanding therapeutic targets in bladder cancer: The PI3K/Akt/mTOR pathway. Lab Invest. 90:1406–1414. 2010. View Article : Google Scholar : PubMed/NCBI
24	Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP and Wu X: Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 31:1387–1391. 2010. View Article : Google Scholar : PubMed/NCBI
25	To KK, Au-Yeung SC and Ho YP: Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anticancer Drugs. 17:673–683. 2006. View Article : Google Scholar : PubMed/NCBI
26	Mehta RG, Murillo G, Naithani R and Peng X: Cancer chemoprevention by natural products: How far have we come? Pharm Res. 27:950–961. 2010. View Article : Google Scholar : PubMed/NCBI
27	Chi BH, Kim SJ, Seo HK, Seo HH, Lee SJ, Kwon JK, Lee TJ and Chang IH: P70S6K and Elf4E dual inhibition is essential to control bladder tumor growth and progression in orthotopic mouse non-muscle invasive bladder tumor model. J Korean Med Sci. 30:308–316. 2015. View Article : Google Scholar : PubMed/NCBI
28	Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE and Retz M: S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One. 6:e275092011. View Article : Google Scholar : PubMed/NCBI
29	Tavares MR, Pavan IC, Amaral CL, Meneguello L, Luchessi AD and Simabuco FM: The S6K protein family in health and disease. Life Sci. 131:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
30	Arroyo DS, Gaviglio EA, Ramos JM Peralta, Bussi C, Rodriguez-Galan MC and Iribarren P: Autophagy in inflammation, infection, neurodegeneration and cancer. Int Immunopharmacol. 18:55–65. 2014. View Article : Google Scholar : PubMed/NCBI
31	Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
32	Zhang WG, Liu XF, Meng KW and Hu SY: Puerarin inhibits growth and induces apoptosis in SMMC-7721 hepatocellular carcinoma cells. Mol Med Rep. 10:2752–2758. 2014. View Article : Google Scholar : PubMed/NCBI
33	Lin YJ, Hou YC, Lin CH, Hsu YA, Sheu JJ, Lai CH, Chen BH, Lee Chao PD, Wan L and Tsai FJ: Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells. Biochem Biophys Res Commun. 378:683–688. 2009. View Article : Google Scholar : PubMed/NCBI
34	Gan M and Yin X: Puerarin induced in mantle cell lymphoma apoptosis and its possible mechanisms involving multi-signaling pathway. Cell Biochem Biophys. 71:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
35	Gao Z, Wei B and Qian C: Puerarin injection for treatment of unstable angina pectoris: A meta-analysis and systematic review. Int J Clin Exp Med. 8:14577–14594. 2015.PubMed/NCBI
36	Liang F and Xie S: Puerarin prevents tumor necrosis factor-α-induced apoptosis of PC12 cells via activation of the PI3K/Akt signaling pathway. Exp Ther Med. 14:813–818. 2017. View Article : Google Scholar : PubMed/NCBI
37	Li H, Dong L, Liu Y, Wang G, Wang G and Qiao Y: Biopharmaceutics classification of puerarin and comparison of perfusion approaches in rats. Int J Pharm. 466:133–138. 2014. View Article : Google Scholar : PubMed/NCBI
38	Liu X, Ding Y, Zhao B, Liu Y, Luo S, Wu J, Li J and Xiang D: In vitro and in vivo evaluation of puerarin-loaded PEGylated mesoporous silica nanoparticles. Drug Dev Ind Pharm. 42:2031–2037. 2016. View Article : Google Scholar : PubMed/NCBI